Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of 162 in Chronic Hepatitis B
NCT06159062Phase 1Terminated
- Sponsor
- Yangshengtang
- Start
- Jun 2024
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing 162 with Placebo (2 arms). Primary endpoint: Adverse event (consists of dose limited toxicity). Started Jun 2024; status: terminated.
02
Drugs
YST-162
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06159062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06159062.